Wegovy vs Mounjaro: Which Offers Better Value for Money?
Is Wegovy Better Than Mounjaro for Budget-Conscious Patients?
When evaluating whether Wegovy is better than Mounjaro from a cost perspective, several factors come into play beyond the initial price point. Wegovy (semaglutide) is a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, representing different mechanisms of action that may suit different patient needs. The question of whether Wegovy is better than Mounjaro often depends on individual response, tolerance, and budget considerations.
At EverydayMeds, we've structured our pricing to make Wegovy accessible without compromising on quality or clinical support. Our transparent pricing model means you know exactly what you'll pay, with no hidden fees for consultations or prescriptions. Both medications require careful dose escalation and ongoing medical supervision, making the total cost of treatment an important consideration for long-term weight management success.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
Our Wegovy pricing structure reflects the different phases of treatment, starting with the 0.25mg starter dose at £79.99 (after FIRST40 discount for new customers). The dose escalation continues with 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the maintenance 2.4mg dose at £209.99. Returning customers benefit from our DOSE25 discount code, ensuring continued affordability throughout their treatment journey.
For those seeking convenience and continuity, our bundle options provide excellent value whilst ensuring uninterrupted treatment. The Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first two months of treatment. Our Ultimate Stability Trio offers three months of maintenance 2.4mg doses for £649.99, providing peace of mind for established patients. All prices include clinical assessment, prescription, and next-day temperature-controlled delivery across the UK.
Clinical Evidence: Is Wegovy Better Than Mounjaro in Trials?
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, highlighting Wegovy's broader health benefits beyond weight management.
Mounjaro's SURMOUNT trials showed different results, but direct comparisons aren't appropriate due to varying trial designs, patient populations, and endpoints. Both medications represent significant advances in weight management, and the question of whether Wegovy is better than Mounjaro should be determined by your prescriber based on your individual medical history, treatment goals, and response to therapy.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of a naturally occurring hormone responsible for regulating blood sugar and appetite. When considering whether Wegovy is better than Mounjaro, it's important to understand that Wegovy works specifically on GLP-1 receptors in the brain's appetite centres, promoting feelings of fullness and reducing food cravings. This mechanism may help slow gastric emptying, meaning food stays in your stomach longer, contributing to sustained satiety between meals. The medication is designed to be used alongside a reduced-calorie diet and increased physical activity, forming part of a comprehensive weight management approach. Unlike some weight loss treatments, Wegovy's effects on appetite regulation may help address the psychological aspects of overeating and food cravings.
Streamlined Ordering Process for Both Wegovy and Mounjaro
Our efficient ordering process begins with a comprehensive 3-minute online clinical assessment, designed to gather essential medical history and current health information. Once submitted, our qualified prescribers review your assessment within 3 working days (or 24 hours with our express service), ensuring appropriate treatment selection whether you're considering Wegovy or Mounjaro. Upon approval, your prescription-only medicine is dispatched via next-day delivery using specialist cold-chain packaging to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and patient safety throughout the process. Follow-up support is available through our clinical team, helping you navigate any questions about treatment effectiveness, side effects, or dosing adjustments.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy offers a significant storage advantage that may influence your decision when comparing whether Wegovy is better than Mounjaro for your lifestyle. Once removed from the fridge, Wegovy remains stable at room temperature (below 30°C) for up to 6 weeks, compared to Mounjaro's 21-day room temperature stability. The FlexTouch pen design provides precise dosing with an easy-to-use injection mechanism, suitable for once-weekly administration. Proper refrigeration at 2-8°C before first use ensures medication potency, whilst the extended room temperature stability makes travel and daily life more convenient. The mandatory dose escalation schedule (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg) helps minimise side effects whilst optimising therapeutic response. Each pen contains four doses, clearly marked with dosage information for patient safety and confidence.
UK Market Position: Why Wegovy vs Mounjaro Matters for Cost-Conscious Patients
The UK weight management market has evolved significantly with the introduction of both Wegovy and Mounjaro, creating options for patients who previously had limited pharmaceutical support. When evaluating whether Wegovy is better than Mounjaro from a health economics perspective, consider the total cost of ownership including potential long-term health benefits and reduced comorbidity risks. NICE guidance (TA875) recommends Wegovy with specialist weight management support, providing additional validation for treatment access and potential future NHS availability.
Our competitive pricing strategy reflects the understanding that effective weight management shouldn't be limited to those who can afford premium prices. Both medications represent significant investment in long-term health, and the question of whether Wegovy is better than Mounjaro often comes down to individual response and sustained adherence. By offering transparent pricing and flexible payment options, we're democratising access to evidence-based weight management treatments across the UK.
Making Your Decision: Wegovy or Mounjaro at EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which is right for you based on your medical history, treatment goals, and individual circumstances. Our clinical team considers factors including previous weight loss attempts, medical comorbidities, medication tolerance, and lifestyle factors when recommending treatment options. With Wegovy starting from £79.99 using discount codes FIRST40 (new customers) or DOSE25 (returning customers), we've made evidence-based weight management accessible without compromising clinical standards. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, or explore our comprehensive range of weight management treatments. Remember that successful weight management requires commitment to lifestyle changes alongside pharmaceutical support, and our team is here to support you throughout your journey with either medication choice.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
